Author:
Manoharan Anitha,Atmakur Harshita,Dutta Majumder Parthopratim,Biswas Jyotirmay
Abstract
AbstractA 47-year-old woman with hypertension and rheumatoid arthritis presented with non-necrotizing scleritis in both eyes. Despite a course of oral corticosteroids, she continued to experience persistent symptoms. A rheumatologist was consulted and initiated treatment with tofacitinib, a JAK/STAT inhibitor. Treatment with tofacitinib and oral corticosteroids resulted in an improvement in the scleritis in both eyes. However, a fundus examination of her left eye revealed a superior-temporal branch retinal vein occlusion. Given the growing concern regarding the increased risk of thromboembolic events with tofacitinib therapy, it is essential to consider the risk of retinal vascular occlusions when starting tofacitinib therapy, particularly in patients with underlying systemic comorbidities.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Ophthalmology
Reference12 articles.
1. Pyare R, Kaushik V, Dutta Majumder P, Biswas J (2020) Tofacitinib in recalcitrant scleritis: first case report from India. Indian J Ophthalmol 68(9):1988–1990. https://doi.org/10.4103/ijo.IJO_534_20
2. Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ (2019) Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 13:53–55. https://doi.org/10.1016/j.ajoc.2018.12.001
3. Pyare R, Dutta Majumder P, Shah M, Kaushik V, Agarwal M, Biswas J (2022) Tofacitinib in Scleritis: a Case Series. Ocul Immunol Inflamm Published online September 20:1–7. https://doi.org/10.1080/09273948.2022.2113805
4. Dhillon S, Tofacitinib (2017) A review in rheumatoid arthritis. Drugs 77(18):1987–2001. https://doi.org/10.1007/s40265-017-0835-9
5. Pfizer (2023) PHASE 3B/4 Randomized safety endpoint study of 2 doses of tofacitinib in comparison to a tumor necrosis factor (TNF) INhibitor in subjects with rheumatoid arthritis. clinicaltrials.gov; 2021. Accessed April 3, https://clinicaltrials.gov/ct2/show/NCT02092467